patritumab
daiichi sankyo
['patritumab', 'breast']
komen-funded researcher ian krop reported data showing an overall response rate of 20-50% depending on breast cancer subtype from an ongoing phase 1/2 study of patritumab deruxtecan, an antibody-drug conjugate (adc) for patients with her3+ #metastatic #breastcancer at #asco22 
A force united by a promise to end breast cancer, funding groundbreaking research, community health & advocacy programs globally.
https://t.co/dvoS7vv1mZ